METHOD FOR PREVENTION OF POSTOPERATIVE INFLAMMATORY CONDITIONS AFTER CATARACT PHACOEMULSIFICATION Russian patent published in 2025 - IPC A61B3/00 G01N33/53 

FIELD: medicine.

SUBSTANCE: present invention refers to medicine, namely to ophthalmology, and can be used for prevention of postoperative inflammatory conditions after cataract phacoemulsification. To this end, the patient is examined for the presence of preoperative risk factors for developing postoperative inflammatory conditions, which include rheumatic diseases, systemic hypertension, a preoperative dilated pupil diameter of less than 6 mm, atonic iris syndrome, uveitis, retinal vein occlusion, epiretinal membrane, age over 75 years old and under 40 years old, diabetic macular oedema, diabetic retinopathy, history of eye trauma and surgical operations on this eye, leukocyte count is more than 10.0 × 10⁹/l, absolute lymphocyte count less than 1.0 × 10⁹/l, blood fibrinogen level is more than 4 mg/l, C-reactive protein level is more than 10 mg/l, erythrocyte sedimentation rate is more than 20 mm/h. Further, during the cataract phacoemulsification operation, the occurrence of intraoperative risk factors for the development of postoperative inflammatory conditions is recorded, which include atonic iris syndrome, a surgical injury of the iris, rupture of posterior capsule or capsulotomy, entrapment of iris, presence of residual lens masses, loss of vitreous body, presence of suture material in anterior chamber of the eye, extracapsular fixation of intraocular lenses or operation duration of more than 60 minutes. If one of the preoperative or intraoperative risk factors is detected at the end of the operation, solution containing 0.2–0.4 mg of dexamethasone is introduced and as broad-spectrum antibiotic 0.5 mg of moxifloxacin solution or 1 mg of cefuroxime solution.

EFFECT: invention provides reducing the risk of postoperative inflammatory conditions: anterior segment toxic reaction syndrome, postoperative formation of fibrin and hypopyon in the eye cavity, formation of anterior and posterior synechiae, cystic macular oedema, anterior capsule contraction, posterior capsule opacity, acute postoperative endophthalmitis, infectious and non-infectious keratitis, episcleritis and scleritis, postoperative iridocyclitis, uveitis and vitritis, due to a personalized approach, and also provides improved clinical and functional results of the operation and patient's quality of life.

1 cl, 2 ex